| A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) (NCT07156578) | Rhythm Pharmaceuticals, Inc. | 2025-11-10 |
| A Study of Setmelanotide in Patients With Prader-Willi Syndrome (NCT06772597) | Rhythm Pharmaceuticals, Inc. | 2025-03-04 |
| Open-Label Extension Study of Setmelanotide (NCT06596135) | Rhythm Pharmaceuticals, Inc. | 2024-10-21 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity (NCT06046443) | Rhythm Pharmaceuticals, Inc. | 2024-07-11 |
| A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment (NCT06239116) | Rhythm Pharmaceuticals, Inc. | 2024-03-05 |
| A Trial of Setmelanotide in Acquired Hypothalamic Obesity (NCT05774756) | Rhythm Pharmaceuticals, Inc. | 2023-04-26 |
| Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity (NCT04966741) | Rhythm Pharmaceuticals, Inc. | 2022-03-08 |
| Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway (NCT05194124) | Rhythm Pharmaceuticals, Inc. | 2021-12-21 |
| EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway (NCT05093634) | Rhythm Pharmaceuticals, Inc. | 2021-12-10 |
| DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway (NCT04963231) | Rhythm Pharmaceuticals, Inc. | 2021-11-30 |
| Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants (NCT05046132) | Rhythm Pharmaceuticals, Inc. | 2021-08-05 |
| Open-Label Study of Setmelanotide in Hypothalamic Obesity (NCT04725240) | Rhythm Pharmaceuticals, Inc. | 2021-06-07 |
| A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment (NCT04348175) | Rhythm Pharmaceuticals, Inc. | 2020-07-09 |
| An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes (NCT03621007) | Rhythm Pharmaceuticals, Inc. | 2019-08-06 |
| Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity (NCT03746522) | Rhythm Pharmaceuticals, Inc. | 2018-11-23 |
| Long Term Extension Trial of Setmelanotide (NCT03651765) | Rhythm Pharmaceuticals, Inc. | 2018-07-15 |
| The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry (NCT03479437) | Rhythm Pharmaceuticals, Inc. | 2018-04-15 |
| Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity (NCT03287960) | Rhythm Pharmaceuticals, Inc. | 2018-01-30 |